PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE)
Ms. Napolitano1, M. Mattana2, C. Cammarata1, M. Leotta3, S. Linari4, M.E. Mancuso5, G. F. Rivolta6, C. Santoro7, L. Valdrè8, R.C. Santoro3, S. Siragusa1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; 2Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; 4Center for Bleeding Disorders, Careggi University Hospital, Firenze; 5Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; 6Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; 7Hematology, University Hospital Policlinico Umberto I, Roma; 8Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Women carriers of hemophilia A and B (HC-A, HC-B) or affected by hemophilia A and B (HW-A, HW-B) are often asymptomatic, they may however bleed during pregnancy and delivery. This study investigated pregnancy and childbirth outcomes in HC and HW managed in Italy. The primary aim was to define the frequency and severity of bleeding complications during pregnancy, delivery, and postpartum and evaluate their correlation with FVIII/FIX levels. We examined delivery approaches and treatment needs.
Methods: This retrospective multicenter study was conducted on behalf of the Italian Association of Hemophilia Centers (AICE). Following IRBs approval, HC and HW were enrolled between January 2022 and December 2024. Collected data, referring to any pregnancy and delivery managed between December 2011 and December 2021, included: age, ISTH-BAT score, genetic diagnosis, CBC, FVIII:c/FIX:c levels, prenatal diagnosis, pregnancy history, mode of delivery, postpartum bleeding, transfusional or pharmacological support.
Results: Overall 94 women were recruited: 48 HC-A, 27 HW-A,11 HC-B, 4 HW-B; median age at haemophilia diagnosis was 27 years (2-45); median ISTH-BAT score was 1,74 (0-11). Data from 174 pregnancies were analyzed: 95 vaginal births, 59 cesarean sections,10 miscarriages. Prenatal diagnosis was performed in 99 pregnancies (56,8%). Twelve bleeding episodes during pregnancy (6,7%) and 20 postpartum bleedings (12,9%) were record. At delivery, 31 women (20%) received treatment. Five patients (3,2%) required treatment postpartum. Overall 3 women required blood and one also plasma transfusion. There was no correlation between bleeding episodes and treatment (p=0,297) or factor levels (p=1,2). An inverse correlation between ISTH-BAT score and factor levels was observed (p=0,08) (Table 1).
Conclusions: Bleeding risk in carriers of haemophilia is not only determined by factor levels, other concomitant risk factors play a role. Specific protocols are needed to ensure a safer multidisciplinary approach. Table 1.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
